In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ESC Congress 2016 Hot Lines target heart failure, prevention and coronary artery disease

ESC Congress 2016 will be held 27 to 31 August in Rome, Italy

Sophia Antipolis, 27 July 2016: The highly anticipated ESC Congress 2016 hot lines are set to reveal the latest discoveries in the fields of heart failure, cardiovascular disease (CVD) prevention, and coronary artery disease in six packed sessions.

Six Hot Lines sessions:

Innovative approaches for the treatment of heart failure (HF) will be presented in five trials:

  • DANISH: Effect of implantable cardioverter defibrillator on mortality in non-ischaemic systolic HF
  • REM-HF: Evaluation of implantable devices using remote monitoring
  • MORE-CARE: Impact of remotely monitoring biventricular defibrillators on outcomes and resources
  • CHART-1: Cardiopoietic regenerative therapy for congestive HF
  • Allogeneic mesenchymal stem cells for non-ischaemic cardiomyopathy

> Link to session details 

Preventive strategies will be unveiled in acute coronary syndromes (ACS), sleep apnoea, and hypertension:

  • NIPPON: Optimal dual antiplatelet treatment duration following bioabsorbable drug eluting stent
  • ANTARCTIC: Platelet function monitoring in elderly patients stented for ACS
  • SAVE: Results from the sleep apnoea cardiovascular endpoints study
  • NACIAM: Early N-acetylcysteine with glyceryl trinitrate in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention

> Link to session details

Novel preventive treatments in lipids will be released:

  • HIJ-PROPER: LDL cholesterol targeting with pitavastatin plus ezetimibe
  • OPTICARE: Trial of educational and behavioural intervention for cardiac rehabilitation
  • Effect of long-term lower LDL cholesterol, lower systolic blood pressure, or both on risk of CVD
  • ESCAPE: Effect of alirocumab on frequency of lipoprotein apheresis
  • Apheresis as a novel treatment for refractory angina with raised lipoprotein(a)

> Link to session details

The use of imaging in the diagnosis and management of coronary artery disease will be discussed:

  • CONSERVE: Direct versus selective catheterisation guided by coronary computed tomography (CT) in stable coronary artery disease
  • DOCTORS: Does Optical Coherence Tomography Optimise Results of Stenting?
  • CE-MARC 2: Diagnostic strategies in patients with suspected coronary heart disease
  • PACIFIC trial: Head-to-head comparison of coronary CT angiography, myocardial perfusion SPECT, PET, and hybrid imaging for diagnosis of ischaemic heart disease
  • AMERICA: Multivascular versus coronary disease treatment alone

> Link to session details

Coronary artery disease and stenting is the focus of a dedicated session:

  • NorStent: Long term effects of new generation drug eluting versus contemporary bare metal stents
  • BASKET-SAVAGE: Drug eluting versus bare metal stents in saphenous vein grafts
  • PRAGUE -18: Ticagrelor versus prasugrel in ST-segment elevation myocardial infarction
  • Antithrombotic therapy without stenting for patients with ACS caused by plaque erosion
  • BBK II: Culotte versus T-stenting for treatment of coronary bifurcation lesions

> Link to session details

New preventive strategies:

  • ENSURE-AF: Edoxaban for cardioversion of atrial fibrillation
  • ANNEXA-4: Andexanet alfa to reverse Factor Xa inhibitors in acute major bleeding
  • REVERSE II: Identifying venous thromboembolism patients who can discontinue anticoagulants
  • YEARS: Simplified diagnostic management algorithm for acute pulmonary embolism

> Link to session details

Additional late breaking science will be presented with 25 clinical trial updates, 24 registries and 12 basic and translational hot lines presentations.

Original science will also be showcased in the different abstract sessions - the Advances in Science, Rapid Fire Abstracts, and Moderated Posters, Best Posters and traditional posters. Topics of particular interest to the press will be featured in four press conferences on the cardiovascular (CV) risks of modern life, stroke and arrhythmias, heart failure, and preventing sudden death.


Four Press conferences:

The cardiovascular risks of modern life - Saturday 27 August 12:30-13:30

  • Leisure time physical activity reduces risk of CV death and acute CVD events in older adults
  • Healthy School, Happy School: randomised clinical trial designed to stop obesity in children
  • Low socioeconomic status linked with recurrent CVD events in population with stable CHD
  • Personal activity index for promotion of physical activity and prevention of CVD


Stroke and arrhythmia – life or death- Saturday 27 August 15:00-16:00

  • PRAGUE-16: Direct catheter-based thrombectomy for the treatment of acute ischaemic stroke
  • Detecting atrial fibrillation using existing smartphones without add-ons
  • Alcohol abuse is associated with increased risk of ischemic stroke in low risk patients with non-valvular atrial fibrillation
  • Stroke and mortality with non-vitamin K antagonist oral anticoagulation versus warfarin in AF


Heart failure – challenges and solutions - Sunday 28 August 13:00-14:00

  • Protective effect of nebivolol on anthracycline-induced cardiotoxicity
  • Increasing readmissions to hospital worsen mortality and decrease survival in heart failure patients
  • AGES-Reykjavik Study: heart failure in the elderly and predictions for the future
  • High morbidity and mortality risk in HF and under treatment with evidence based therapies

Preventing sudden death – diet or device - Sunday 28 August 15:00-16:00

  • Risk of motor vehicle accidents in patients with an implantable cardioverter defibrillator
  • Major disparities in implementation of public access defibrillation programmes
  • MOLI-SANI study: Mediterranean diet associated with lower risk of mortality in patients with CVD
  • Circumstances of sudden death in hypertrophic cardiomyopathy


Register now to secure your place at the largest and most influential cardiovascular congress of the year.





Notes to editor

ESC Press Office
Tel: +33 (0)4 89 87 24 83
Emails: -


Journalists planning to attend are invited to register here


If you have any questions, please contact


The press conference timetable is available here


* On AlphaGalileo and EurekAlert, Hot Line releases will only be available when the embargo is lifted, online and on-site


* Press conference releases will be available a few days before congress and the embargo is lifted at the start of the press conferences.


* ESC Media and Embargo Policy available here


* ESC Congress 2016 will take place from 27 to 31 August at the Fiera di Roma in Rome, Italy

* Information on Late Breaking Science at ESC Congress is available here


* The scientific programme is available here.

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 95 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.


About ESC Congress 2016

ESC Congress is the world’s largest and most influential cardiovascular scientific conference contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy.


More information is available from the ESC Press Office at